InvestorsHub Logo
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: DewDiligence post# 6995

Tuesday, 01/15/2008 6:34:05 AM

Tuesday, January 15, 2008 6:34:05 AM

Post# of 19309
The PPL trial was the worst and BTW they used transgenic protein as you know.
Telecris trial which was not placebo controlled (CF patients):

http://clinicaltrials.gov/ct2/show/NCT00486837?term=Alpha1-antitrypsin+inhaled&rank=2

and the Baxter/Arriva which was a safety trial of inhaled
recombinant alpha 1-antitrypsin in subjects with alpha 1-antitrypsin deficiency:

http://clinicaltrials.gov/ct2/show/NCT00161707?term=Alpha1-antitrypsin+inhaled&rank=3

Both did not continue with the inhaled program but a trend was seen and published:

http://www.ncbi.nlm.nih.gov/pubmed/17050563?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Kamada thinks that their ATT is better and that the Pari's device is superior. I personally think the odds are not high.



Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.